Cardiolipin-targeted mitochondrial research peptide.
SS-31 selectively associates with the inner mitochondrial membrane via cardiolipin binding.
Stabilizes cardiolipin–cytochrome c interaction, preserving cristae architecture and electron-transport efficiency.
Peptide engages target receptor with high affinity.
Downstream intracellular pathways activate.
Gene expression and protein synthesis shift.
Measurable change in the studied biomarker.
Tested SS-31 in renal ischemia-reperfusion with electron microscopy of mitochondria.
Preserved cristae structure, restored ATP synthesis and reduced tubular injury.
First randomized dose-escalation trial of elamipretide in PMM patients.
Improved 6-minute walk distance at higher doses with favorable tolerability.
Comprehensive pharmacology of cardiolipin-targeted mitochondrial protection.
Established class as first-in-class bioenergetic restorers vs. antioxidant scavengers.
Lyophilized -20°C, light-protected.
Strictly for in-vitro laboratory and research investigations.
Not approved for diagnostic, therapeutic, or veterinary application.
Handling restricted to licensed researchers and laboratory staff.
Warning — SS-31 (Elamipretide) is supplied solely for legitimate laboratory research. Any administration to humans or animals is strictly prohibited and may violate federal, state, or local law. By purchasing, the researcher accepts full responsibility for safe handling, storage, and lawful use.
